TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01811225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose Progesterone
Description: The low progesterone dose is seven days of placebo Tri-sprintec + placebo generic Prometrium twice a day (7AM and 7PM).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low-dose Progesterone
Description: The low progesterone dose is seven days of placebo Tri-sprintec + placebo generic Prometrium twice a day (7AM and 7PM).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose Progesterone
Description: The high progesterone dose is seven days of placebo Tri-Sprintec + 200mg of generic Prometrium twice a day (7AM and 7PM).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose Progesterone
Description: The high progesterone dose is seven days of placebo Tri-Sprintec + 200mg of generic Prometrium twice a day (7AM and 7PM).
Study: NCT02910115

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold laparotomy sponges
Description: Cold laparotomy sponges are lap sponges that are saturated in sterile, iced normal saline

Intervention type: DRUG
Group type: OTHER
Intervention: Pitocin
Description: Pitocin is administered intravenously according to the usual protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pitocin
Description: Pitocin is administered intravenously according to the usual protocol.
Study: NCT04612439

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VABB Elite 10G
Description: If the biopsy device is a vacuum-assisted Elite 10G needle, insert the needle groove into the mass and rotate to cut the biopsy tissue one circle

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BARD 14G CNB
Description: If the biopsy device is a BARD 14G hollow core needle, insert the needle to the edge of the mass and pull the trigger in different directions to eject the needle to retrieve the material
Study: NCT02645201

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Gastrus
Description: to compare Gastrus 4x108 tbl twice a day to placebo tbl

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: to compare Gastrus 4x108 tbl twice a day to placebo tbl
Study: NCT02397031

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: weekly psychotherapy sessions for 10 weeks (120 min each)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: interpersonal effectiveness
Description: weekly psychotherapy sessions for 10 weeks (120 min each)
Study: NCT02135770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin
Description: 10 unit/kgBW/hour continuous infusion for 72 hours
Study: NCT03088371

Intervention type: DRUG
Group type: OTHER
Intervention: Bupivacaine 0.25%
Description: For psoas sciatic block.

Intervention type: OTHER
Group type: OTHER
Intervention: Pajunk Needle
Description: For local anaesthesia application in psoas sciatic block

Intervention type: OTHER
Group type: OTHER
Intervention: Portex combined spinal epidural kit
Description: For combined spinal epidural anaesthesia

Intervention type: DRUG
Group type: OTHER
Intervention: Lidocaine 1%
Description: For psoas sciatic block.

Intervention type: DRUG
Group type: OTHER
Intervention: Bupivacaine 0.5%
Description: For spinal anaesthesia in combined spinal epidural anaesthesia.
Study: NCT03884101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib 4 mg or 10 mg capsules at a total daily dose of 20 mg taken by mouth once per day.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg IV infusion given on Day 1 of each cycle.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 175 mg/m\^2 IV infusion given on Day 1 of each cycle.
Study: NCT01313676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone furoate/vilanterol
Description: 100/25mcg given once daily via novel dry powder inhaler
Study: NCT03884101

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin 10 mg/mL IV infusion at a total dose of are-under-the-curve (AUC) 6 (per Calvert's formula) given on Day 1 of each cycle.
Study: NCT03995979

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 4 Day Protein Restricted Diet
Description: Subjects will follow a 4 day protein restricted diet using Scandishake® mixed with almond milk which will be provided. They may also drink water. No food, other beverages, or alcohol may be consumed. The amount of diet to be consumed will be calculated for each patient based upon resting energy expenditures plus additional energy needs. These will be consumed by the study subjects at home in an unrestricted manner, in that they may be consumed at any point of time in the day.
Study: NCT00442546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pregabalin
Description: 300 mg/day (double blind)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03088371

Intervention type: DRUG
Group type: OTHER
Intervention: Lidocaine 2 %
Description: For psoas sciatic block in the post-operative period

Intervention type: DRUG
Group type: OTHER
Intervention: Lidocaine 2 %
Description: For psoas sciatic block in the post-operative period

Intervention type: DRUG
Group type: OTHER
Intervention: Bupivacaine 0.125 %
Description: For combined spinal epidural in the post-operative period.
Study: NCT04686695

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: taVNS
Description: taVNS was applied using a Huatuo stimulator (SDZ-IIB) developed by Suzhou manufacture of Medical Device and Material. Stimulation parameters was 1 mA of electrical current at a frequency of 20 Hz with pulse duration ≤ 1 ms, for 30min,administered twice daily.
Study: NCT00287365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ozone
Description: 2 hour exposure to 0.4 ppm ozone
Study: NCT04401826

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tunneling micro-surgical crown lengthening approach using piezo-surgery
Description: excess gingiva is eliminated. 2 mm bone is removed from CEJ-bone crest with piezo surgery via tunneling

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Micro-surgical crown lengthening approach using Piezosurgery
Description: excess gingiva is eliminated. 2 mm bone is removed from CEJ-bone crest with piezo surgery with conventional flap elevation.
Study: NCT03788629

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Talocrural joint MWM mobilization
Description: There were two groups for this study. In addition to Bobath Concept, talocrural joint mobilization was performed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Subtalar joint MWM mobilization
Description: There were two groups for this study. In addition to treatment of control group, subtalar joint mobilization was performed.
Study: NCT02994069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: XRT
Description: Radiation Therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: XRT
Description: Radiation Therapy
Study: NCT01313676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone furoate
Description: 100mcg given once daily via novel dry powder inhaler

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vilanterol
Description: 25mcg given once daily via novel dry powder inhaler
Study: NCT02502162

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDN

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill
Study: NCT02311959

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nipple sparing mastectomy
Description: Standardized surgical procedure by :~* Nipple sparing mastectomy with nipple core histopathology.~* Immediate breast reconstruction (flap and/or implant).~* +/- lymph node evaluation (sentinel node procedure or axillary dissection).
Study: NCT01909453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGX818
Description: LGX818- Orally 100 mg and 50 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGX818
Description: LGX818- Orally 100 mg and 50 mg capsules
Study: NCT02642302

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIIT With 60 sec Rest
Description: 30 sessions of High intensity interval training (all out) with 30 seconds of stimulous with 60 seconds rest on VO2Max and aerobic/ anaerobic performance

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIIT With120 sec Rest
Description: 30 sessions of High intensity interval training (all out) with 30 seconds of stimulous with 120 seconds rest on VO2Max and aerobic/ anaerobic performance

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Continuous exercise at 50-55% VO2Max with similar total work of interval training
Study: NCT02451943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaratumab
Description: Administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Administered IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Doxorubicin
Description: Administered IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV
Study: NCT03401385

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Datopotamab Deruxtecan (Dato-DXd)
Description: A total anti-TROP2 antibody and MAAA-1181a

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Datopotamab Deruxtecan (Dato-DXd)
Description: A total anti-TROP2 antibody and MAAA-1181a

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroid Containing Mouthwash
Description: A mouthwash containing a steroid ingredient administered in sub-study

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-Steroid Containing Mouthwash
Description: A mouthwash containing a non-steroid ingredient administered in sub-study
Study: NCT01922570

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: nutrition
Description: comparion of enteral versus enteral and supplemental parenteral nutrition
Study: NCT03416218

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prognosis
Description: Prognosis will be a single-player 2D, digital simulation game and supporting multimedia website. Players are situated as a major official of Hexacago, and tasks them with managing the city's finances, education levels, and health concerns to lower rates of teenage pregnancy and sexually transmitted infections. In the game Prognosis, player dispatches professionals from a variety of fields to different neighborhoods around the city, observing the effects of their resource allocation decisions across multiple systems over many in-game months. The supporting multimedia website will house curriculum and learning tools to support the learning objectives of Prognosis.
Study: NCT03720015

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: Physical exercise controlled program supervised by an accredited exercise specialist

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional management
Description: Nutritional management controlled by a PhD clinical and sport nutrition specialist
Study: NCT00535197

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infusion of autologous CD34+ stem cells into middle cerebral artery
Description: intra-arterial infusion into ipsilateral MCA, via trans-femoral approach
Study: NCT04730336

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tixel
Description: Peri-Orbital fractional treatment on the Eye-Lid to assess the effect on Dry Eye symptoms
Study: NCT04295538

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elezanumab
Description: Solution for infusion; Intravenous (IV)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for infusion; Intravenous (IV)
Study: NCT00982254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral insulin
Description: oral insulin capsule formulation (150 U insulin/200 mg 4-CNAB in one capsule); single dose administration of 300 U insulin (in two capsules) and of 150 U insulin (one capsule) on two separate dosing days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: regular human insulin
Description: subcutaneous injection of 15 U regular human insulin; single dose administration on one separate dosing visit.
Study: NCT02077738

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFCWO (Hill-Rom Vest™ Airway Clearance System)
Description: study subjects in the HFCWO group received HFCWO for 15 min twice a day for 5 days after extubation
Study: NCT04417556

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sleep measurement
Description: Sleep measurement with polysomnography, actigraphy, and Thai-version Richards Campbell Sleep Questionnaire.
Study: NCT00691158

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pramlintide (Amylin)
Description: 4.7 mls of Amylin 15mcg/ml IV bolus.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Normal Saline)
Description: 4.7 mls normal saline IV bolus x1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2 Metreleptin
Description: Receive .06mg/kg of metreleptin IV bolus x1

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leptin plus Pramlintide
Description: receive leptin IV bolus x1 and pramlintide bolus at Timepoint +0 and +30 minutes.
Study: NCT03139175

Intervention type: DEVICE
Group type: OTHER
Intervention: balance assessment with Biodex balance system
Description: All subjects of three groups will be assessed with the evaluation device( balance system).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: balance assessment with Biodex balance system
Description: All subjects of three groups will be assessed with the evaluation device( balance system).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: balance assessment with Biodex balance system
Description: All subjects of three groups will be assessed with the evaluation device( balance system).
Study: NCT01032850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib & Capecitabine
Description: Intervention: Sorafenib twice a day by mouth (400mg), Capecitabine twice a day by mouth (850mg). One cycle of treatment will consist of capecitabine on days 1-7 and 15-22 while sorafenib will be given daily continuously. Cycles will be repeated every 28 days.
Study: NCT03612115

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation
Description: Neuromuscular electrical stimulation to the bilateral deltoid and quadriceps femoris muscles with 50 Hz for 3 days/week, 8 weeks.~Device name: Four-channel Wireless Professional (DJO United Kingdom Ltd., Chattanooga, France)
Study: NCT04448743

Intervention type: OTHER
Intervention: Blood sample
Description: 20 Ml blood sample

Intervention type: OTHER
Intervention: Blood sample
Description: 20 Ml blood sample

Intervention type: OTHER
Intervention: Blood sample
Description: 20 Ml blood sample
Study: NCT03545490

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Early nutritional intervention
Description: Early nutritional intervention (Ensure) was given two weeks before radiotherapy. Ensure 3 times per day, Mixing 55.8 g or 6 spoons of Ensure with 190 mL of warm water.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Early nutritional intervention
Description: Early nutritional intervention (Ensure) was given two weeks before radiotherapy. Ensure 3 times per day, Mixing 55.8 g or 6 spoons of Ensure with 190 mL of warm water.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Early nutritional intervention
Description: Early nutritional intervention (Ensure) was given two weeks before radiotherapy. Ensure 3 times per day, Mixing 55.8 g or 6 spoons of Ensure with 190 mL of warm water.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Early nutritional intervention
Description: Early nutritional intervention (Ensure) was given two weeks before radiotherapy. Ensure 3 times per day, Mixing 55.8 g or 6 spoons of Ensure with 190 mL of warm water.
Study: NCT03089346

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Magnetic Resonance Imaging (MRI) with Ultrashort Echo Time (UTE)
Description: Magnetic Resonance Imaging (MRI) with Ultrashort Echo Time (UTE) pulse sequences on a 1.5T magnet (Avanto dot, Siemens) with 3D reconstruction of the bronchial tree using Neko-MR software in asthma in order to assess bronchial thickness.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Computed tomography (CT)
Description: Computed tomography (CT) on a Definition 64 (Siemens) with 3D reconstruction of the bronchial tree using Neko-3D software in asthma in order to assess bronchial thickness.
Study: NCT01076920

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells
Description: 60x106 MSCs Trans-endocardial intramyocardial injections (n=14-16)
Study: NCT04057508

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Modulation of muscle sympathetic nerve activity
Description: Assessment of muscle sympathetic nerve signal and exposition to external non invasive modulation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Modulation of muscle sympathetic nerve activity
Description: Assessment of muscle sympathetic nerve signal and exposition to external non invasive modulation.
Study: NCT00566111

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ceftriaxone
Description: 2g per day which will be administered IV via midline, 7 days a week for 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: Saline solution will be administered IV via midline, 7 days a week for 4 weeks.
Study: NCT03808831

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fall detection and prevention system
Description: The fall detection and prevention system records near-fall and fall events; meanwhile, it alarms subjects while detecting near-fall events and alarms caregivers while detecting fall events.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham fall detection and prevention system
Description: The sham system with record but no alert function
Study: NCT01868464

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG TICE strain
Description: All doses: Tice Bacillus Calmette-Guerin (BCG) will be administered as a single 0.1 ml ID injection over the deltoid muscle of the preferred arm. Groups 1 - 4 will receive one dose of Tice BCG intradermally at 2x10\^6 cfu, 4x10\^6 cfu, 8x10\^6 cfu and 16x10\^6 cfu, respectively.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG TICE strain
Description: All doses: Tice Bacillus Calmette-Guerin (BCG) will be administered as a single 0.1 ml ID injection over the deltoid muscle of the preferred arm. Groups 1 - 4 will receive one dose of Tice BCG intradermally at 2x10\^6 cfu, 4x10\^6 cfu, 8x10\^6 cfu and 16x10\^6 cfu, respectively.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG TICE strain
Description: All doses: Tice Bacillus Calmette-Guerin (BCG) will be administered as a single 0.1 ml ID injection over the deltoid muscle of the preferred arm. Groups 1 - 4 will receive one dose of Tice BCG intradermally at 2x10\^6 cfu, 4x10\^6 cfu, 8x10\^6 cfu and 16x10\^6 cfu, respectively.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCG TICE strain
Description: All doses: Tice Bacillus Calmette-Guerin (BCG) will be administered as a single 0.1 ml ID injection over the deltoid muscle of the preferred arm. Groups 1 - 4 will receive one dose of Tice BCG intradermally at 2x10\^6 cfu, 4x10\^6 cfu, 8x10\^6 cfu and 16x10\^6 cfu, respectively.
Study: NCT00479323

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Pneumovax 23
Description: Licensed pneumococcal vaccine (Pneumovax 23).
Study: NCT04108871

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prostate Biopsy
Description: Samples of tissue are removed from the prostate for histopathological diagnosis of prostate cancer through the use of a needle with the assistance of transrectal ultrasound.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Prostate Biopsy
Description: Samples of tissue are removed from the prostate for histopathological diagnosis of prostate cancer through the use of a needle with the assistance of transrectal ultrasound.
Study: NCT01811680

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Variable Speed and Sensing Treadmill
Description: open label study on variable speed and sending treadmill training for hemiplegic gait training.